| Literature DB >> 26553318 |
Puxiongzhi Wang1,2, Jingkun Zhao3,4, Xiao Yang3,4, Shaopei Guan3,4, Hao Feng5, Dingpei Han6, Jun Lu3, Baochi Ou3, Runsen Jin6, Jing Sun3,4, Yaping Zong3,4, Bo Feng3, Junjun Ma7, Aiguo Lu8,9, Minhua Zheng3,4.
Abstract
Prefoldin (PFDN) subunits have been reported upregulated in various tumor types, while the expression and functions of PFDN1 (PFDN subunit 1) in colorectal cancer (CRC) are not well elucidated. The aim of this study was to investigate the use of PFDN1 as a poor prognosis indicator for CRC and explore the functions of PFDN1 in CRC. The relationship between PFDN1 expression and CRC clinical-pathological statistics was detected on the tissue microarray containing 145 cases of CRC. ShRNA was used to silence PFDN1 expression in SW480 and RKO CRC cells, and these transfected cells were analyzed for changes in proliferation, colony formation, cell cycle, migration, and invasion. Immunofluorescence and immunoblot were used to determine the remodeling of the F-actin and α-tubulin. Finally, tumor growth on nude mice was observed and measured. In this study, we found PFDN1 was upregulated in CRC tissues compared with adjacent normal tissues. Also, PFDN1 expression positively correlated with tumor size and tumor invasion. Moreover, after silencing PFDN1 in SW480 and RKO cells, the proliferation and motility of CRC cells were significantly suppressed. The inhibitory effect of PFDN1 on tumor cell growth and motility was partially due to G2/M cell cycle blockage and cytoskeletal deficiency. Finally, in vivo assay showed that downregulation of PFDN1 inhibited tumor growth on nude mice and PFDN1 expression correlated with higher levels of Ki-67 staining. These findings indicate that PFDN1 was involved in the progression of CRC, and provide new insights into PFDN1 as a potential therapeutic target for CRC treatment.Entities:
Keywords: Colorectal cancer; Cytoskeletal reorganization; Migration and invasion; PFDN1; Proliferation
Mesh:
Substances:
Year: 2015 PMID: 26553318 DOI: 10.1007/s12032-015-0710-z
Source DB: PubMed Journal: Med Oncol ISSN: 1357-0560 Impact factor: 3.064